These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1381659)

  • 1. [Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2].
    Mir LM; Roth C; Orlowski S; Belehradek J; Fradelizi D; Paoletti C; Kourilsky P
    C R Acad Sci III; 1992; 314(12):539-44. PubMed ID: 1381659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses.
    Mir LM; Orlowski S; Poddevin B; Belehradek J
    Eur Cytokine Netw; 1992; 3(3):331-4. PubMed ID: 1379837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of the tumoral growth induced by the injection of histo-incompatible cells producing interleukin-2].
    Roth C; Mir LM; Cressent M; Quintin-Colonna F; Belehradek J; Ley V; Fradelizi D; Kourilsky P
    C R Acad Sci III; 1992; 314(11):499-504. PubMed ID: 1521169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Electrochemotherapy, a new antitumor treatment: first clinical trial].
    Mir LM; Belehradek M; Domenge C; Orlowski S; Poddevin B; Belehradek J; Schwaab G; Luboinski B; Paoletti C
    C R Acad Sci III; 1991; 313(13):613-8. PubMed ID: 1723647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
    Yoshida R; Yoneda Y; Kuriyama M; Kubota T
    J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
    Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
    Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of repeated cycles of local IL-2 injections in mice carrying slowly growing tumour grafts.
    Símová J; Bubeník J; Indrová M; Bubeníková D; Jandlová T
    Folia Biol (Praha); 1993; 39(6):315-22. PubMed ID: 7926162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour effectiveness of hyperthermia is potentiated by local application of electric pulses to LPB tumours in mice.
    Karner KB; Lesnicar H; Cemazar M; Sersa G
    Anticancer Res; 2004; 24(4):2343-8. PubMed ID: 15330182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2.
    Mir LM; Roth C; Orlowski S; Quintin-Colonna F; Fradelizi D; Belehradek J; Kourilsky P
    J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):30-8. PubMed ID: 7537154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
    Lichtor T; Glick RP; Tarlock K; Moffett S; Mouw E; Cohen EP
    Cancer Gene Ther; 2002 May; 9(5):464-9. PubMed ID: 11961669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
    Aruga A; Aruga E; Chang AE
    Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intracavitary administration of cyclophosphamide, interleukin-2 and lymphokine activated killer cells against established intraperitoneal tumor.
    Eggermont AM; Sugarbaker PH
    Acta Med Austriaca; 1989; 16(3-4):47-50. PubMed ID: 2609913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
    Vondrys P; Símová J; Takácová S; Jandlová T; Bubeník J
    Folia Biol (Praha); 1997; 43(1):39-40. PubMed ID: 9158948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
    Bubeník J; Indrová M; Toulcová A
    Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.